Among the benefits for Moderna, Inc. in converting its COVID-19 vaccine emergency use authorization to an approved biologics license application was the ability to drop a negative comparison about myocarditis adverse events from its label.
Labeling for Spikevax, Moderna’s mRNA vaccine approved on 31 January, includes language in the warnings and precautions section about myocarditis...







